

Lorenzo Pradelli – Albert Wertheimer

Pharmacoeconomics

Principles and Practice

Expanded and updated edition



Edited by
Lorenzo Pradelli
Albert Wertheimer

© 2022 The Author(s)
Materials published under CC BY-NC 4.0 license
(<https://creativecommons.org/licenses/by-nc/4.0>).

Permission for commercial re-use must be secured in writing from:

© **SEEd srl**
Via Magenta 35 – 10128 Torino, Italia
Tel. +39.011.566.02.58
www.seedstm.com
info@seedstm.com

Second edition September 2022
(first edition December 2012)
ISBN 978-88-97419-69-3

<https://doi.org/10.7175/693>

Cover image:
Photo 104668458 © Kesinee Srisura | Dreamstime.com

Although the information about medication given in this book has been carefully checked, the author and publisher accept no liability for the accuracy of this information. In every individual case the user must check such information by consulting the relevant literature.

Summary

Preface	1
Introduction	3
Healthcare Dilemma.....	3
Opportunity Cost.....	4
Efficiency and Equity	5
HTA and Pharmacoeconomics	7
Pharmacoeconomics	11
Sensitivity Analysis.....	13
Summary.....	14
Questions.....	15
Answers	16
References and Further Readings.....	17
1 Principles of Epidemiology	19
1.1 Introduction	19
1.2 Study Design	20
Non-Experimental Studies	20
Experimental Studies.....	24
Non-Randomized Studies	31
Systematic and Narrative Reviews.....	32
1.3 Bias in Epidemiology	33
Selection Bias	34
Information Bias.....	35
Confounding.....	36
1.4 Measures of Occurrence	37
Incidence.....	37
Prevalence.....	38
1.5 Measures of Association	39
Contingency Tables	39
Relative Risk	39
Risk Difference	41
Odds Ratio.....	42
Hazard Ratio.....	43

1.6	Regressions: How to Interpret Results	43
	Univariate Linear Regression Model	44
	Multivariate Linear Regression Model.....	46
	Questions.....	48
	Answers	49
	References.....	50
2	Definitions and Basic Concepts	53
2.1	Definitions	53
2.2	Costs	54
2.3	Consequences	56
	Economic Outcomes.....	56
	Patient Outcomes.....	56
2.4	Perspectives	58
2.5	Time Horizon	58
	Discounting.....	59
	Questions.....	61
	Answers	62
	References.....	63
3	Pharmacoeconomic Evaluations	65
3.1	Introduction	65
3.2	Cost Analysis	66
	Cost of Care.....	66
3.3	Cost-Outcomes Analysis	67
	Cost-Effectiveness.....	67
3.4	Multicriteria Decision Analysis	70
	Example: MCDA in Communicable e Non-Communicable Disease	71
	Cost-Utility.....	73
	Cost-Minimization.....	73
	Cost-Benefit	73
	Cost-Consequence Analysis.....	74
3.5	Utility	74
3.6	Psychometrics	75
	Questions.....	78
	Answers	81
	References.....	82

4	Modeling Frameworks	85
4.1	Introduction	86
4.2	Microsimulation or Cohort Modeling?	87
	Example: Microsimulation Model in HIV	88
4.3	Steps in Decision Analysis	89
	Example: How to Develop a Model for Emergency Contraception and Pregnancy?... 89	
	Problem Conceptualization.....	89
	Model Conceptualization.....	90
	Model Parameter Estimation	92
	Run the Model and Interpretation.....	93
	Sensitivity Analysis, Transparency, and Validation	95
4.4	Markov Models.....	96
	Example: Markov Model in the Treatment of Secondary Hyperparathyroidism.....	97
4.5	Partitioned Survival Models.....	100
	Example: PSM in Advanced or Unresectable Hepatocellular Carcinoma.....	100
4.6	Discrete-Event Simulation.....	103
	Example: DES Model in TPN.....	103
4.7	Discretely Integrated Condition Event Simulation.....	106
	Example: How to Develop a DICE Model in Cancer	107
4.8	Agent-Based Models	108
	Example: AB Model in Screening Program	109
4.9	Conclusions	110
	Questions.....	112
	Answers	114
	References	115
5	Budget Impact Analysis	119
5.1	Introduction	119
5.2	Example: Budget Impact Analysis of Apixaban to Treat and Prevent Venous Thromboembolism in Italy	122
	Questions.....	126
	Answers	126
	References.....	127
6	Patient Reported Outcomes	129
6.1	From Physiological Measures to Patient Reported Outcome	130

6.2	Quality of Life, Health-Related Quality of Life, and Patient Reported Outcomes.....	131
	Quality of Life	131
	Health-Related Quality of Life	132
	Patient Reported Outcomes	133
6.3	Individual Health and Circumstantial Perceptions and Experiences.....	134
6.4	Applications of PRO Instruments.....	136
6.5	Identifying an Appropriate Instrument for Measuring PRO	138
6.6	When are the Results of PROs Relevant?	141
6.7	Summary and Conclusion	142
	Questions.....	143
	Answers	144
	References.....	145
7	Data Sources and Accounting for Uncertainty	153
7.1	Data Sources.....	153
	Clinical Epidemiology	154
	Literature Analysis	155
	Clinical Studies.....	161
	Administrative Databases.....	161
	Financial Data	164
7.2	Statistical Analysis.....	164
7.3	Accounting for Uncertainty	166
	Definition of Error	166
	Principal Sources of Error in Clinical Studies.....	166
	Reducing Error in Clinical Studies.....	167
	Selection Bias in Subjects Entering the Study.....	167
	Selection Bias in Subjects After Entering the Study	170
7.4	Pharmacoeconomic Studies	170
	Sensitivity Analysis	170
7.5	Conclusions: Evaluating Pharmacoeconomic Studies	177
	Questions.....	178
	Answers	181
	References.....	182
	Glossary	187
	Authors	193